Consistently with this observation, low expression of RBM47 in basal-like breast cancer patients was associated with poor overall survival (log-rank test p = 0.031, HR = 3.36, 95% IC:[1.05–10.79] Fig. 6h, i), which supports previous experimental evidence of a role for RBM47 in supressing breast cancer metastasis and progression [56]. Here, RBM47 is linked to breast carcinoma.